Author Archives: Inês Martins PhD

Symdeko and Orkambi Seen to Also Ease Inflammation in CF Patients

In addition to restoring CFTR protein function in cells, the cystic fibrosis (CF) therapies Orkambi (lumacaftor/ivacaftor) and Symdeko (tezacaftor/ivacaftor combo) significantly reduce the excessive inflammation that damages patients’ lungs, a recent study suggests. Symdeko seems to be more potent than Orkambi at dampening inflammatory responses.